Literature DB >> 23445192

The benefits and risks of alemtuzumab in multiple sclerosis.

Daniel Ontaneda, Jeffrey A Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23445192     DOI： 10.1586/eci.13.1

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


× No keyword cloud information.
  4 in total

Review 1.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 2.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

3.  Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0)--Development of an Outcome Instrument for Educational Interventions.

Authors:  C Heesen; J Kasper; K Fischer; S Köpke; A Rahn; I Backhus; J Poettgen; L Vahter; J Drulovic; A Van Nunen; Y Beckmann; K Liethmann; A Giordano; G Fulcher; A Solari
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

Review 4.  Teriflunomide and its mechanism of action in multiple sclerosis.

Authors:  Amit Bar-Or; Andrew Pachner; Francoise Menguy-Vacheron; Johanne Kaplan; Heinz Wiendl
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.